1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
JW Holdings Corporation

JW Holdings Corporation

096760.KS
JW Holdings CorporationKR flagKorea Exchange
3,665.00
KRW
-110.00
- -
253.58BMarket Cap
JW Holdings Corporation
096760.KS
(Korea Exchange)

Recent

price

3,665.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8,117.2
7,772.5
7,861.27
8,142.82
8,397.24
8,623.27
9,795.14
9,436.31
10,008.37
9,863.51
10,597.61
11,081.86
11,961.58
12,926.28
12,390.41
13,937.39
13,953.83
Revenue per Share
-169.35
-483.7
-338.32
273.61
-160.06
2.51
-123.91
748.59
319.68
-388.49
122.91
-39.03
306.49
265
874
841
989.81
Basic EPS, GAAP
-674.47
-1,691.13
-586.41
-1,071.09
-491.39
-510.15
-632.26
-210.02
2,347.88
965.81
694.55
928.43
474.81
376.24
867.98
1,566.42
1,328.08
Free Cash Flow per Basic Share
74.54
65.11
66.71
60.49
60.23
56.64
103.03
140.67
297.79
211.74
216.99
203.41
213.34
247.1
239.66
266.32
-1.66
Dividend per Share
591.68
80.73
-269.2
-48.35
-245.61
-293.81
-525.23
201.05
1,232.4
481.69
563.97
514.21
830.58
989.1
1,711.34
2,453.42
2,530.03
Book Value per Share
2,470.63
2,220.04
1,549.23
2,021.82
1,472.38
2,289.64
2,529.67
2,440.85
2,920.14
1,886.95
1,963.57
1,755.44
2,213.74
2,838.28
4,114.22
5,001.11
5,103.32
Tangible Book Value per Share
68
66
65
65
68
72
70
72
72
74
74
71
72
72
72
70
70
Basic Weighted Avg Shares
554,240
516,012
511,946
530,263
573,920
622,825
684,839
680,970
725,366
728,082
781,515
788,937
864,536
928,072
887,710
969,565
973,257
Sales/Revenue/Turnover
6.49
2.4
0.72
3.85
3.18
5.37
6.33
6.1
4.59
0.83
4.78
8.71
13.11
15.66
16.53
17.32
18.25
Operating Margin (%)
21,371
27,106
28,966
25,405
20,270
21,718
22,226
32,026
34,962
41,574
42,910
38,383
40,126
44,222
41,089
43,643
44,479
Depreciation Expense
-11,563
-32,112
-22,032
17,817
-10,940
181
-8,663
54,022
23,169
-28,676
9,064
-2,778
22,152
19,026
62,618
58,505
69,037
Net Income, GAAP
- -
- -
- -
24.74
- -
- -
226.3
0.08
1,696.5
- -
85.65
86.35
34.53
41.89
22.35
19.94
20.18
Effective Tax Rate (%)
-2.09
-6.22
-4.3
3.36
-1.91
0.03
-1.27
7.93
3.19
-3.94
1.16
-0.35
2.56
2.05
7.05
6.03
7.09
Profit Margin (%)
6,454
-40,353
-189,386
-108,872
-11,417
-22,176
84,049
57,269
142,217
-77,488
-146,833
-50,084
-207,831
-233,306
-43,504
-55,818
-151,254
Working Capital
210,937
210,250
174,780
106,590
215,274
157,889
213,287
252,263
239,955
163,779
89,670
211,257
73,593
42,482
170,341
101,247
17,778
LT Debt
256,854
246,623
205,462
236,025
207,756
270,306
277,591
370,603
400,997
335,294
324,351
304,823
333,263
348,755
521,395
594,627
605,848
Total Equity
- -
- -
- -
1.77
- -
- -
-6.11
4.2
-51.5
- -
0.62
1.17
9.14
9.8
12.56
14.32
15
Return on Invested Capital (%)
- -
- -
- -
6.82
- -
- -
-5.6
9.89
-55.06
- -
2.24
-0.93
1.83
3.07
3.22
2.04
1.42
Return on Capital (%)
-36.96
-140.35
- -
- -
- -
- -
- -
- -
44.63
-45.93
23.5
-7.11
45.85
29.04
64.68
39.9
45.86
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
282,964
258,371
348,722
LT Borrowings
77,199
83,100
- -
LT Finance Leases
18,539
18,147
17,778
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
225,442
251,347
275,855

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
424,046
400,913
411,951
Cash, Cash Equivalents & STI
85,431
89,526
84,669
Accounts Receivable, Net
150,821
137,548
141,340
Inventories
164,600
156,575
161,530
Total Current Liabilities
479,505
456,732
563,205
Payables & Accruals
- -
- -
- -
ST Debt
282,964
258,371
348,722
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.63%
14.3%
14.05%
Free Cash Flow
-118.96%
33.03%
75.23%
Net Income, GAAP
-683.12%
-163.91%
-6.57%
Sales/Revenue/Turnover
4.64%
4.55%
9.22%
Total Cash Common Dividend
22.11%
3.34%
7.9%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
222,982
214,733
226,489
223,506
887,710
2025
239,530
228,383
244,088
257,565
969,565
2026
243,221
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
178
412
181
- -
874
2025
144
57.38
309.98
- -
841
2026
297
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.77
349.53
-117.97
- -
239.66
2025
- -
- -
-1.66
- -
266.32
2026
- -
- -
- -
- -
- -
Similar Companies
Amryt Pharma plc (AMYT.L)
RavenQuest BioMed Inc. (RVVQF)
AstraZeneca Pharma India Limited (ASTRAZEN.NS)
Pure Extracts Technologies Corp. (PRXTF)
Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS)
LiveWire Ergogenics, Inc. (LVVV)
Business
JW Holdings Corporation operates as a holding company for healthcare businesses, primarily engaged in the development, manufacturing and export of pharmaceuticals, medical devices, infusion solutions and related products through subsidiaries including JW Pharmaceutical, JW Shinyak, JW Life Science and JW Medical; core offerings encompass antibiotics such as carbapenems including the generic Imipenem, antifungal agents, hyperlipidemia drugs, electrolyte additives, amino acid solutions, gastrointestinal agents, wound care products, eye care treatments, liver disease therapies, cold medicines, active pharmaceutical ingredients, oral and topical analgesics, cosmetics like hair dye and beauty care items, non-PVC infusion containers, tubes and bags, 3D digital mammography equipment, MRI and CT scanners, sterilizers, operating room equipment, infant care systems and health supplements. The company conducts operations in South Korea, the United States, Japan, China and other international markets. Founded in 1945 and headquartered in Gwacheon-si, South Korea, JW Holdings recently advanced its anti-cancer drug development through a collaboration between JW Pharmaceutical and U.S.-based Tempus AI utilizing clinical data and organoids, integrated its AI platforms Jewelry and Clover with expanded capabilities, progressed STAT3 inhibitor JW2286 as a first-in-class innovative drug, achieved positive Phase 3 data for a gout treatment with IND approvals in five Asian countries and secured research funding for novel compounds targeting XBP1s and Wnt signaling pathways.